T. Van-gelder, Therapeutic Drug Monitoring for Mycophenolic Acid Is Value for (Little) Money, Clinical Pharmacology & Therapeutics, vol.90, issue.2, pp.203-207, 2011.
DOI : 10.1097/TP.0b013e3181d75952

R. Byrne, S. Yost, and B. Kaplan, Mycophenolate Mofetil Monitoring: Is There Evidence That It Can Improve Outcomes?, Clinical Pharmacology & Therapeutics, vol.48, issue.2, pp.204-210, 2011.
DOI : 10.1056/NEJMoa067411

P. Pillans, R. Rigby, P. Kubler, C. Willis, P. Salm et al., A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients, Clinical Biochemistry, vol.34, issue.1, pp.77-81, 2001.
DOI : 10.1016/S0009-9120(00)00196-X

M. Okamoto, Y. Wakabayashi, A. Higuchi, Y. Kadotani, S. Ogino et al., Therapeutic Drug Monitoring of Mycophenolic Acid in Renal Transplant Recipients, Transplantation Proceedings, vol.37, issue.2, pp.859-60, 2005.
DOI : 10.1016/j.transproceed.2004.12.238

T. Pawinski, M. Durlik, I. Szlaska, A. Urbanowicz, J. Majchrnak et al., Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant, Journal of Clinical Pharmacy and Therapeutics, vol.47, issue.1, pp.27-34, 2006.
DOI : 10.1097/00007691-200102000-00007

S. Satoh, H. Tada, M. Murakami, N. Tsuchiya, T. Inoue et al., The Influence of Mycophenolate Mofetil Versus Azathioprine and Mycophenolic Acid Pharmacokinetics on the Incidence of Acute Rejection and Infectious Complications After Renal Transplantation, Transplantation Proceedings, vol.37, issue.4, pp.1751-1754, 2005.
DOI : 10.1016/j.transproceed.2005.03.072

D. Kuypers, K. Claes, P. Evenepoel, B. Maes, and Y. Vanrenterghem, Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients, Clinical Pharmacology & Therapeutics, vol.75, issue.5, pp.434-481, 2004.
DOI : 10.1016/j.clpt.2003.12.009

K. Benson and A. Hartz, A Comparison of Observational Studies and Randomized, Controlled Trials, New England Journal of Medicine, vol.342, issue.25, pp.1878-86, 2000.
DOI : 10.1056/NEJM200006223422506

J. Meakins, Innovation in surgery: the rules of evidence, The American Journal of Surgery, vol.183, issue.4, pp.399-405, 2002.
DOI : 10.1016/S0002-9610(02)00825-5

T. Van-gelder, L. Hilbrands, Y. Vanrenterghem, W. Weimar, D. Fijter et al., A RANDOMIZED DOUBLE-BLIND, MULTICENTER PLASMA CONCENTRATION CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ORAL MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION1, Transplantation, vol.68, issue.2, pp.261-267, 1999.
DOI : 10.1097/00007890-199907270-00018

L. Meur, Y. Büchler, M. Thierry, A. Caillard, S. Villemain et al., Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation, American Journal of Transplantation, vol.82, issue.1, pp.2496-503, 2007.
DOI : 10.1097/00007691-200412000-00005

T. Van-gelder, H. Silva, D. Fijter, J. Budde, K. Kuypers et al., Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial, Transplantation, vol.86, issue.8, pp.1043-51, 2008.
DOI : 10.1097/TP.0b013e318186f98a

T. Van-gelder, T. Silva, H. , D. Fijter, J. Budde et al., Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid, Transplantation, vol.89, issue.5, pp.595-604, 2010.
DOI : 10.1097/TP.0b013e3181ca7d84

A. Prémaud, L. Meur, Y. Debord, J. Szelag, J. Rousseau et al., Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods, Therapeutic Drug Monitoring, vol.27, issue.3, pp.354-61, 2005.
DOI : 10.1097/01.ftd.0000162231.90811.38

L. Meur, Y. Thierry, A. Glowacki, F. Rerolle, J. Garrigue et al., Early Steroid Withdrawal and Optimization of Mycophenolic Acid Exposure in Kidney Transplant Recipients Receiving Mycophenolate Mofetil, Transplantation, vol.92, issue.11, pp.1244-51, 2011.
DOI : 10.1097/TP.0b013e318234e134
URL : https://hal.archives-ouvertes.fr/hal-01151208

A. Prémaud, A. Rousseau, L. Meur, Y. Venisse, N. Loichot et al., Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: Pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients, Pharmacological Research, vol.61, issue.2, pp.167-74, 2010.
DOI : 10.1016/j.phrs.2009.09.006

L. Meur, Y. Borrows, R. Pescovitz, M. Budde, K. Grinyo et al., Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting, Transplantation Reviews, vol.25, issue.2, pp.58-64, 2011.
DOI : 10.1016/j.trre.2011.01.002
URL : https://hal.archives-ouvertes.fr/hal-01151023

D. Kuypers, L. Meur, Y. Cantarovich, M. Tredger, M. Tett et al., Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation, Clinical Journal of the American Society of Nephrology, vol.5, issue.2, pp.341-58, 2010.
DOI : 10.2215/CJN.07111009

F. Saint-marcoux, S. Vandierdonck, A. Prémaud, J. Debord, A. Rousseau et al., Large Scale Analysis of Routine Dose Adjustments of Mycophenolate Mofetil Based on Global Exposure in Renal Transplant Patients, Therapeutic Drug Monitoring, vol.33, issue.3, pp.285-94, 2011.
DOI : 10.1097/FTD.0b013e31821633a6
URL : https://hal.archives-ouvertes.fr/inserm-00590457

D. Rizopoulos, JM: an R package for the Joint Modeling of Longitudinal and Time-toevent Data, J Stat Softw, vol.35, pp.1-33, 2010.

A. Tsiatis and M. Davidian, Joint modeling of longitudinal and time-to-event data: an overview, Stat Sin, vol.14, pp.809-843, 2004.

M. Yu, N. Law, J. Taylor, and H. Sandler, Joint longitudinal-survival-cure models and their application to prostate cancer, Stat Sin, vol.14, pp.835-62, 2004.

H. Jacqmin-gadda, R. Thiébaut, and J. Dartigues, Mod??lisation conjointe de donn??es longitudinales quantitatives et de d??lais censur??s, Revue d'??pid??miologie et de Sant?? Publique, vol.52, issue.6, pp.502-512, 2004.
DOI : 10.1016/S0398-7620(04)99090-6

Z. Zhou, J. Shen, Y. Hong, S. Kaul, M. Pfister et al., Time-Varying Belatacept Exposure and Its Relationship to Efficacy/Safety Responses in Kidney-Transplant Recipients, Clinical Pharmacology & Therapeutics, vol.58, issue.2, pp.251-258, 2012.
DOI : 10.1038/clpt.2012.84

D. Rizopoulos, Dynamic Predictions and Prospective Accuracy in Joint Models for Longitudinal and Time-to-Event Data, Biometrics, vol.63, issue.9, pp.819-848, 2011.
DOI : 10.1111/j.1541-0420.2010.01546.x

K. Solez, R. Colvin, L. Racusen, M. Haas, B. Sis et al., Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions, American Journal of Transplantation, vol.23, issue.4, pp.753-60, 2008.
DOI : 10.1046/j.1523-1755.1999.00299.x

P. Hougaard, Fundamentals of Survival Data, Biometrics, vol.50, issue.1, pp.13-22, 1999.
DOI : 10.1111/j.0006-341X.1999.00013.x

D. Rizopoulos, G. Verbeke, and G. Molenberghs, Multiple-Imputation-Based Residuals and Diagnostic Plots for Joint Models of Longitudinal and Survival Outcomes, Biometrics, vol.53, issue.1, pp.20-29, 2010.
DOI : 10.1111/j.1541-0420.2009.01273.x

T. Pawinski, M. Durlik, I. Szlaska, A. Urbanowicz, J. Ostrowska et al., The Weight of Pharmacokinetic Parameters for Mycophenolic Acid in Prediction of Rejection Outcome: The Receiver Operating Characteristic Curve Analysis, Transplantation Proceedings, vol.38, issue.1, pp.86-95, 2006.
DOI : 10.1016/j.transproceed.2005.11.084

V. Armstrong, M. Shipkova, E. Schütz, L. Weber, B. Tönshoff et al., Monitoring of mycophenolic acid in pediatric renal transplant recipients, Transplantation Proceedings, vol.33, issue.1-2, pp.1040-1043, 2001.
DOI : 10.1016/S0041-1345(00)02322-8

L. Shaw, M. Korecka, R. Venkataramanan, L. Goldberg, R. Bloom et al., Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies, American Journal of Transplantation, vol.48, issue.5, pp.534-576, 2003.
DOI : 10.1097/00007691-200108000-00001

R. Van-hest, T. Van-gelder, R. Bouw, T. Goggin, R. Gordon et al., Time-dependent clearance of mycophenolic acid in renal transplant recipients, British Journal of Clinical Pharmacology, vol.41, issue.6, pp.741-52, 2007.
DOI : 10.1097/01.ftd.0000199358.80013.bd

G. Levy, E. Thervet, J. Lake, and K. Uchida, Patient management by Neoral C2 monitoring: An international consensus statement1, Transplantation, vol.73, issue.Supplement, pp.12-20, 2002.
DOI : 10.1097/00007890-200205151-00003

F. Cosio, H. Amer, J. Grande, T. Larson, M. Stegall et al., Comparison of Low Versus High Tacrolimus Levels in Kidney Transplantation: Assessment of Efficacy by Protocol Biopsies, Transplantation, vol.83, issue.4, pp.411-417, 2007.
DOI : 10.1097/01.tp.0000251807.72246.7d

A. Webster, R. Woodroffe, R. Taylor, J. Chapman, and J. Craig, Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data, BMJ, vol.331, issue.7520, pp.810-831, 2005.
DOI : 10.1136/bmj.38569.471007.AE

Y. Lee, B. Kim, J. Lee, Y. Kim, D. Kim et al., Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up, Transplant International, vol.7, issue.2, pp.147-54, 2010.
DOI : 10.1111/j.1432-2277.2009.00955.x

S. Sandrini, N. Aslam, R. Tardanico, G. Setti, N. Bossini et al., Tacrolimus versus cyclosporine for early steroid withdrawal after renal transplantation, Journal of Nephrology, vol.25, issue.1, pp.43-52, 2012.
DOI : 10.5301/jn.5000070

T. Van-gelder, H. Silva, D. Fijter, H. Budde, K. Kuypers et al., How Delayed Graft Function Impacts Exposure to Mycophenolic Acid in Patients After Renal Transplantation, Therapeutic Drug Monitoring, vol.33, issue.2, pp.155-64, 2011.
DOI : 10.1097/FTD.0b013e31820c0a96

J. Karczewski, M. Karczewski, and K. Wiktorowicz, Preliminary study evaluating the risk factors of kidney acute rejection, Centr Eur J Immunol, vol.36, pp.233-239, 2011.

O. Gensburger, V. Schaik, R. Picard, N. , L. Meur et al., Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil, Pharmacogenetics and Genomics, vol.20, issue.9, pp.537-580, 2010.
DOI : 10.1097/FPC.0b013e32833d8cf5
URL : https://hal.archives-ouvertes.fr/inserm-00494526